đ§ This Week in Immunology: Pediatric Crohn’s Breakthroughs, Dupixent Approval, and more Advancements in Autoimmune Therapies
Stay up to date with the latest developments in immunologyâfrom pediatric treatments and autoimmune therapy innovations to real-world data and strategic partnerships in the field:
đ„ Johnson & Johnson Seeks FDA Approval for pediatric Crohnâs treatment, supported by Phase 3 UNITI-Jr data, addressing the increasing need in pediatric patients.
đ CreakyJoints Dominates Social Media at the European Rheumatology Conference, surpassing 62,000 views and featuring 12 interviews with top rheumatologists and patient advocates.
đ€ Geneoscopyâs ColoSense Validates Impact in colorectal cancer screening, showing a 14 to 23 percent reduction in CRC deaths and now included in the 2025 NCCN guidelines.
đȘđș Emrosi Data to be Presented at SDPA 2025 Dermatology Conference, with strong efficacy for rosacea treatment, independent of body weight, simplifying patient management.
đ FDA Approves Dupixent for Bullous Pemphigoid treatment, the first targeted therapy for this autoimmune skin disorder in adults, based on ADEPT trial success.
𧏠Real-World Efficacy of Upadacitinib and Abrocitinib in atopic dermatitis, showing significant improvements after one year with no new safety concerns.
đĄ argenx Announces VYVGART Approval for CIDP in Europe, marking the first new treatment for this rare autoimmune condition in over 30 years.
đ Candid Therapeutics Advances T-Cell Engagers for autoimmune diseases, including ongoing clinical trials for conditions like rheumatoid arthritis and lupus.
đŹ Immutep Announces Positive Phase I Data for IMP761, a promising LAG-3 agonist antibody showing effective T-cell suppression without adverse effects.
đ§Ș AltruBio Presents Data for ALTB-268 in T-cell mediated inflammatory diseases, showing efficacy in animal models of colitis and graft-versus-host disease.
đ Harbour BioMed Partners with Otsuka to develop BCMAxCD3 bispecific T-cell engagers, advancing new treatments for autoimmune diseases.
đą Stay Ahead in Immunology Research!
â
Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune innovation
#Immunology #FDAApproval #PediatricCrohns #BullousPemphigoid #AutoimmuneDiseases #AtopicDermatitis #ColorectalCancer #ImmunologyResearch #Rheumatology #ClinicalTrials #Biotech #LucidQuest #ImmunologyUpdates #HealthcareInnovation